{"filings":[{"id":1397237,"accession_number":"0001683168-26-005233","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2026-07-02T11:30:21+00:00","items":["7.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals posts investor presentation; no new material details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation posted on company website on July 2, 2026.","Filing includes only cover page and forward-looking statements; no financial or operational data.","No updates on clinical trials, revenue, or guidance provided in this filing.","Full presentation available on company's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95049,"accession_number":"0001683168-26-003432","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"CNS Pharma raises ~$22.5M in private placement at $2.30/sh; board change","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$22.5M from sale of 650K shares at $2.30/sh and pre-funded warrants for 9.14M shares at $2.299/warrant.","Proceeds to identify, acquire, advance new assets and for working capital.","Director Jerzy Gumulka resigns (no disagreement); Michal Fisher appointed independent director.","120-day lock-up on equity sales after registration effective; no variable rate transactions for one year.","Placement agent A.G.P./Alliance Global Partners receives 7% cash fee plus up to $90K expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107840,"accession_number":"0001683168-26-001664","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals posts routine investor presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed Form 8-K indicating it posted a March 2026 investor presentation on its website.","Presentation is available under Exhibits but contains no specific financial or operational updates in the filing.","No earnings, guidance, or material events were disclosed in the presentation text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107839,"accession_number":"0001683168-26-001413","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CNS Pharmaceuticals appoints Lynne Kelley as CMO; former CMO Sandra Silberman departs with severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lynne Kelley appointed CMO effective March 2, 2026; base salary $450K, target bonus 40%.","Initial RSU grant of 9,500 shares; vests 25% at 6 months, 25% at 12 months, balance quarterly.","Severance: 6 months base salary plus prorated bonus and accelerated equity if terminated without cause.","Former CMO Sandra Silberman receives 3 months base salary severance under separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107838,"accession_number":"0001683168-26-001066","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CNS Pharmaceuticals appoints Steve O'Loughlin as CFO; current CFO Downs moves to SVP Finance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve O'Loughlin appointed CFO effective March 2, 2026; base salary $450,000, target bonus 40% of base.","O'Loughlin receives initial RSU grant of 9,500 shares; 25% vest at 6 months, 25% at 12 months, 50% quarterly thereafter.","Current CFO Christopher Downs resigns as CFO, becomes SVP - Finance effective March 2; base salary $350,000, target bonus 30%.","Both employment agreements include 6-month severance (base salary) for termination without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124235,"accession_number":"0001683168-25-009208","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CNS Pharmaceuticals appoints Rami Levin as CEO effective January 1, 2026; John Climaco resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rami Levin becomes CEO and President effective Jan 1, 2026; base salary $580,000, target bonus 50% of base, initial RSU grant of 19,000 shares.","John Climaco resigned as CEO and board member Dec 16, 2025; resignation not due to disagreement; severance includes 12 months salary and $319,000 bonus.","Levin will also join the board; previously CEO of Saniona (2019-2022) and ImStem Biotechnology (2022-2024).","If Levin is terminated without cause or for good reason, severance includes 12 months base salary, target bonus, accelerated equity vesting, and COBRA subsidy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124234,"accession_number":"0001683168-25-008624","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"CNS Pharma shareholders approve 12x increase in authorized common shares to 300M and equity plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 25M to 300M shares; preferred from 416,667 to 5M shares.","2020 Equity Plan shares authorized increased by 114,916 to total 115,061 shares.","All six director nominees elected: Climaco, Gumulka, Keyes, Charles, Cockroft, Mahery.","MaloneBailey LLP ratified as independent auditor for FY 2025; say-on-pay approved with annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140907,"accession_number":"0001683168-25-005284","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals announces 1-for-12 reverse stock split effective July 22, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split reduces outstanding shares from ~6.36M pre-split to ~529,829 post-split.","Authorized common shares reduced from 300M to 25M; preferred from 5M to 416,667.","No fractional shares; cash in lieu for odd lots.","CUSIP changes to 18978H508; trading symbol CNSP unchanged.","Historical per-share data recast: FY2024 basic loss per share goes from ($38.87) pre-split to ($466.43) post-split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140906,"accession_number":"0001683168-25-005129","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals posts July 2025 investor presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["No financial results, guidance, or operational milestones disclosed.","Presentation filed under Item 7.01; no specific news content provided.","No changes to business strategy, leadership, or capital structure reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158666,"accession_number":"0001683168-25-003575","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals raises ~$5.0M in public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 325,000 shares, 3,627,570 pre-funded warrants, and 3,952,570 common warrants.","Combined purchase price: $1.265 per share+common warrant, $1.264 per pre-funded+common warrant.","Gross proceeds ~$5.0M; net proceeds for working capital and general corporate purposes.","Common warrants exercisable at $1.14 for 5 years; pre-funded warrants at $0.001.","Company agreed to 45-day no-issuance and 180-day no variable-rate transaction lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158665,"accession_number":"0001683168-25-002373","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals releases April 2025 investor presentation; no specific news disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated April 2025 furnished under Regulation FD for investor meetings.","Filing does not include any financial results, pipeline updates, or clinical data.","Company ticker CNSP listed; no material new information beyond presentation format.","Confidence low because exhibit content beyond title page was not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177061,"accession_number":"0001683168-25-002140","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CNS Pharmaceuticals regains Nasdaq compliance; subject to one-year monitoring period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated March 31, 2025 confirms regained compliance with $1.00 bid price rule.","Company subject to Mandatory Panel Monitor for one year from letter date.","If noncompliance occurs within monitoring period, no additional cure period allowed; delisting process begins.","Previous reverse stock splits (>250:1 cumulative) disqualified company from standard compliance period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177060,"accession_number":"0001683168-25-001754","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals ups ATM sales capacity to $43.5M from $30.2M; $23.75M raised so far","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company increased aggregate sales price under A.G.P. Sales Agreement to $43.5M on March 20, 2025.","Prior limit was $30.2M; remaining capacity before increase was $6.45M, now total unissued capacity ~$19.75M.","As of March 20, 2025, 2,522,755 shares sold for gross proceeds of ~$23.75M; 2,944,381 shares outstanding.","Shares sold under shelf registration S-3 (File 333-279285) that became effective May 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177059,"accession_number":"0001683168-25-001174","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["3.03","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals announces 1-for-50 reverse stock split effective Feb 21, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-50 ratio effective Feb 21, 2025; shares outstanding reduced from ~136.93M to ~2.74M.","Split intended to increase per-share price to meet Nasdaq minimum bid price listing requirement.","No fractional shares; stockholders receive cash in lieu of fractional shares based on closing price on effective date.","Trading symbol remains \"CNSP\"; new CUSIP 18978H409; par value unchanged at $0.001."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177058,"accession_number":"0001683168-25-000077","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals sold 17.5M shares via ATM; shares outstanding now 74.96M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 17,475,827 shares under at-the-market agreement since last 10-Q (Sept 30, 2024).","As of Jan 3, 2025, common shares outstanding increased to 74,962,533 from ~57.5M.","No disclosure of pricing or use of proceeds; significant dilution (~30%) for existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193840,"accession_number":"0001683168-24-008640","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals holds virtual analyst and investor day; presentation content not detailed in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual analyst and investor day held on December 11, 2024.","Presentation furnished as Exhibit 99.1 was reviewed at the meeting.","No financial results, guidance, or material updates disclosed in the provided exhibit excerpt.","Filing under Item 7.01 Regulation FD; presentation not filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193839,"accession_number":"0001683168-24-008464","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CNS Pharma stockholders approve reverse split (1:2 to 1:50) and warrant repricing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split authorized at ratio between 1-for-2 and 1-for-50; passed with 7,873,677 votes for, 3,121,776 against, 314,908 abstain.","Warrant repricing approved: new exercise price lower of $1.13 per share or closing price on approval date; 1,458,915 for, 1,106,009 against, 171,894 abstain.","Adjournment authorization passed: 8,022,415 for, 2,904,712 against, 383,234 abstain.","Meeting held Nov 26, 2024; quorum of 11,310,361 shares (33.82% of 33,446,403 outstanding) present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193838,"accession_number":"0001683168-24-007533","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq panel grants CNS Pharmaceuticals temporary exception until March 11, 2025 to meet bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq deficiency notice on Sept 12, 2024 for bid price below $1.00 for 30 consecutive days.","Not eligible for standard 180-day compliance period due to cumulative reverse stock splits of 250:1 or more in prior two years.","After hearing, Nasdaq panel granted exception until March 11, 2025 to regain compliance.","Panel reserves right to reconsider; Listing Council may review within 45 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193837,"accession_number":"0001683168-24-007371","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals prices $3M registered direct offering of common stock and pre-funded warrants at $0.17/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3M from sale of 3.7M common shares and pre-funded warrants for 13.9M shares at $0.17/share.","A.G.P./Alliance Global Partners acting as sole placement agent; receives 6.5% fee plus up to $90k expenses.","Closing expected Oct 24, 2024; proceeds for working capital and general corporate purposes.","After partial exercise of pre-funded warrants, company now has 49,574,933 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193836,"accession_number":"0001683168-24-007304","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CNS Pharma faces Nasdaq delisting for bid price deficiency; hearing Nov 5","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 12, 2024, for failing minimum $1.00 bid price for 30 consecutive days.","Ineligible for 180-day cure period due to reverse stock splits >250:1 cumulative ratio in prior two years.","Hearing before Nasdaq Panel scheduled for Nov 5, 2024; automatically stays suspension or delisting pending hearing.","No assurance that Panel will grant an additional compliance extension beyond the hearing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210176,"accession_number":"0001683168-24-006495","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CNS Pharma receives Nasdaq minimum bid deficiency; ineligible for cure due to reverse splits","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified CNS Pharma on Sept 12, 2024 that common stock failed to maintain $1.00 minimum bid for 30 consecutive days.","Company ineligible for 180-day cure period because it effected reverse stock splits with cumulative ratio >=250 in prior two years.","Company intends to request a hearing before Nasdaq Panel; request will automatically stay any suspension/delisting pending hearing.","No assurance that Panel will grant an extension or that company will ultimately regain compliance with listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210175,"accession_number":"0001683168-24-006318","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CNS Pharma regains Nasdaq compliance; subject to one-year Mandatory Panel Monitor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sep 10, 2024, Nasdaq confirmed CNS Pharma has demonstrated compliance with the $2.5M stockholders' equity requirement; delisting matter closed.","Company is subject to a Mandatory Panel Monitor for one year; if non-compliance recurs, immediate delist with no cure period.","Previous extensions from Aug 2023 to Aug 2024 to regain compliance; now resolved with heightened monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210174,"accession_number":"0001683168-24-005311","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CNS Pharmaceuticals regains Nasdaq equity compliance after $9.9M share sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders' equity exceeds $5.0M, above Nasdaq's $2.5M minimum for continued listing.","Sold 23,091,315 shares under A.G.P. agreement for gross proceeds of ~$9.9M.","Cash on deposit $9.6M; company expects to fund operations through Q1 2025.","Nasdaq Panel had granted final extension to Aug 12, 2024; delisting risk now resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210173,"accession_number":"0001683168-24-005145","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CNS Pharma boosts ATM equity facility from $5.2M to $30.2M; $5.19M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 30, 2024, CNS Pharmaceuticals increased the aggregate sales price under its ATM agreement to $25M, for a total of $30.2M including original $5.2M.","As of July 30, 2024, the Company sold 7,206,743 shares for gross proceeds of approximately $5.19 million.","Outstanding shares as of July 30, 2024: 10,075,017; remaining capacity implies significant potential dilution.","Sales are conducted through A.G.P./Alliance Global Partners under an effective S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210172,"accession_number":"0001683168-24-005118","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals in-licenses TPI 287 from Cortice for brain cancer treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CNS Pharmaceuticals entered an exclusive license agreement with Cortice Biosciences for TPI 287, a blood-brain barrier permeable abeotaxane, covering U.S., Canada, Mexico, and Japan.","Upfront consideration includes 616,698 shares of CNS common stock; future milestone payments up to $100M in cash or shares, plus royalties of 3.0%-7.5%.","TPI 287 showed 60% objective response rate and 13.4 months overall survival in a Phase 1 trial with bevacizumab in recurrent GBM.","Company plans to engage FDA in 2025 for a potential registration study of TPI 287 in recurrent glioblastoma.","Topline results from Berubicin pivotal trial expected in first half of 2025; TPI 287 will leverage existing clinical infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210171,"accession_number":"0001683168-24-005070","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CNS Pharma enters $5.2M ATM offering with A.G.P.; warrants repriced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with A.G.P. for at-the-market offering of up to $5.2M common stock; commission 3.0%.","Net proceeds to be used for working capital and general corporate purposes.","Waiver from Feb 2024 investor lifts restrictions on ATM; warrant exercise prices reduced.","Effective Aug 1, 2024, exercise price of 587,028 Series A/B warrants lowered to Minimum Price.","Additional 3,263,000 warrants repricing subject to shareholder approval; proxy statement due within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210170,"accession_number":"0001683168-24-005023","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CNS Pharmaceuticals gets final Nasdaq extension to Aug 12 for equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel granted extension until August 12, 2024 to meet $2.5M stockholders' equity requirement.","Company previously failed to comply with Listing Rule 5550(b) and requested hearing.","This is the full extent of the Panel's discretion; failure to comply may lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210167,"accession_number":"0001683168-24-004772","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K/A","filed_at":"2024-07-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CNS Pharma regains Nasdaq bid price compliance; still faces equity rule delisting risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 5, 2024 confirming bid price compliance (closing bid >=$1.00 for 20 consecutive business days through July 3).","Previously granted extension until July 15, 2024 to demonstrate compliance with both Bid Price and Equity Rules.","Company still not compliant with $2,500,000 stockholders' equity requirement (Nasdaq Listing Rule 5550(b)); further updates expected.","Delisting risk remains if equity compliance not demonstrated by deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210169,"accession_number":"0001683168-24-004708","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CNS Pharmaceuticals regains Nasdaq bid price compliance after 20-day period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter Feb 27, 2024 for bid price below $1.00 for 30 consecutive days.","On July 5, 2024, Nasdaq confirmed compliance as closing bid price ≥ $1.00 for 20 consecutive business days (June 5 – July 3, 2024).","Matter is closed; company continues listing on Nasdaq Capital Market under ticker CNSP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210168,"accession_number":"0001683168-24-004667","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals announces $1.98M registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,425,000 shares at $1.39 per share with common warrants at $1.26 exercise price.","Gross proceeds ~$1.98M; net proceeds for working capital and general corporate purposes.","Closing expected July 5, 2024; warrants expire 5 years from issuance.","A.G.P./Alliance Global Partners acting as financial advisor with 6.5% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228434,"accession_number":"0001683168-24-004501","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals raises ~$1.39M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 568,000 common shares plus warrants for 568,000 shares at $2.45 per unit, gross proceeds ~$1.39M.","Warrants exercisable at $2.32 per share, expire 5 years from issuance; subject to 4.99%/9.99% ownership limitation.","Offering expected to close June 27, 2024; net proceeds for working capital and general corporate purposes.","A.G.P./Alliance Global Partners acting as financial advisor with 6.5% fee plus up to $80,000 expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228426,"accession_number":"0001683168-24-004367","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K/A","filed_at":"2024-06-20T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"CNS Pharmaceuticals files 8-K/A to add legal opinion omitted from prior filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment adds Exhibit 5.1 (ArentFox Schiff legal opinion) inadvertently omitted from June 14 8-K.","No other disclosures in the original filing are modified or updated.","Original 8-K included securities purchase agreement, warrants, financial advisory agreement, and press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228433,"accession_number":"0001683168-24-004253","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals prices $1.37M registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 366,000 shares (or pre-funded warrants) at $3.75/share, with common warrants exercisable at $3.62.","Gross proceeds expected $1.37M; net proceeds for working capital and general corporate purposes.","Closing expected on or about June 17, 2024, subject to customary closing conditions.","Warrants expire 5 years from issuance; cashless exercise if no effective registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228432,"accession_number":"0001683168-24-003998","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals announces 1-for-50 reverse stock split effective June 4, 2024 to meet Nasdaq minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-50 reverse stock split effective 4:01 PM ET June 4, 2024; trading on split-adjusted basis from June 5, 2024 under symbol CNSP.","Outstanding shares reduced from ~16.25M to ~325K; authorized shares remain 300M; par value unchanged at $0.001.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Split intended to increase per share trading price to comply with Nasdaq minimum bid price listing requirement.","Warrants and equity awards proportionally adjusted: shares underlying divided by 50, exercise price multiplied by 50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228431,"accession_number":"0001683168-24-003550","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CNS Pharma Q1 net loss $3.5M; Berubicin GBM trial topline data H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.5M for Q1 2024, vs $4.9M in Q1 2023; R&D expense down to $2.4M from $3.6M.","Cash at March 31, 2024 was ~$0.8M; no revenue reported.","Enrollment completed in potentially pivotal Berubicin trial for GBM; DSMB recommended continuation in Dec 2023.","Topline data from Berubicin study expected first half 2025.","FDA granted Fast Track and Orphan Drug designations for Berubicin."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228430,"accession_number":"0001683168-24-003063","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq Panel grants CNS Pharmaceuticals extension to July 15, 2024 to regain listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Hearing held April 18, 2024; panel grants extension until July 15, 2024.","Must demonstrate compliance with minimum bid price (Rule 5550(a)(2)) and stockholders' equity (Rule 5550(b)).","Company intends to implement its plan to meet the milestones set by the Panel.","Failure to comply by July 15 could result in delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228429,"accession_number":"0001683168-24-002961","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"CNS Pharmaceuticals shareholders approve 4x increase in authorized shares, reverse split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 75M to 300M; 3.5M shares added to 2020 Equity Plan (total 4,345,800).","Board authorized to effect reverse stock split from 1:2 to 1:50 within one year.","Stockholders approved repricing of 3.756M warrants from $1.28 to $0.30 and extension to Feb 2029.","All six director nominees elected; board committees appointed (Audit, Comp, Nominating/Governance).","Ratified MaloneBailey LLP as independent auditor for FY 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228428,"accession_number":"0001683168-24-002359","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CNS Pharmaceuticals posts April 2024 investor presentation; no specific financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing makes available an investor presentation dated April 2024.","Presentation contains only forward-looking statements and risk disclaimers; no new pipeline or financial data.","No changes in guidance, clinical results, or corporate events are reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228427,"accession_number":"0001683168-24-002033","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CNS Pharma FY2023 net loss $18.9M; Berubicin DSMB OK, enrollment done, topline due H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.9M vs $15.3M in 2022; R&D expenses $14.1M (up from $9.3M) on Berubicin trial costs.","Cash at Dec 31, 2023 only $0.5M; subsequent $4.0M public offering extends runway into late Q2 2024.","Berubicin GBM study completed enrollment; DSMB recommended continue without modification after interim futility analysis.","Topline data from potentially pivotal Berubicin trial expected in first half 2025.","Appointed biotech commercialization leader Amy Mahery to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247124,"accession_number":"0001683168-24-001219","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"CNS Pharma receives Nasdaq bid-price deficiency notice; board committee changes","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Feb 27, 2024, Nasdaq notified CNS Pharma common stock bid price closed below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).","Company has 180 days until Aug 26, 2024 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.","This follows a prior delisting notice for failing to meet $2.5M stockholders' equity; hearing requested and stay granted.","Board appointed committee chairs: Audit (Keyes), Compensation (Gumulka), Nominating/Governance (Cockroft) effective Feb 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247123,"accession_number":"0001683168-24-001099","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CNS Pharmaceuticals receives Nasdaq delisting notice over equity shortfall; will request hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified CNSP on Feb 14, 2024, that it failed to meet minimum $2.5M stockholders' equity requirement after extension expired.","Company intends to request a hearing before a Nasdaq Hearings Panel, which will automatically stay suspension or delisting pending the hearing.","Panel may grant an extension not to exceed August 12, 2024, but compliance is not assured.","Previous extension was granted until Feb 13, 2024; company still non-compliant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247122,"accession_number":"0001683168-24-000660","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"CNS Pharma raises $3.7M in $0.30/unit offering; appoints Amy Mahery to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2.2M shares, 11.1M pre-funded warrants, and 26.7M Series A & B warrants at $0.30 per unit.","Gross proceeds ~$3.7M; net proceeds to fund CNS-201 trial and working capital.","Amy Mahery appointed independent director as of Feb 1, 2024; Andrzej Andraczke resigned.","Warrant amendment for 3.756M existing warrants: exercise price reduced to $0.30 if shareholder approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247121,"accession_number":"0001683168-24-000393","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CNS Pharmaceuticals to appoint Amy Mahery as independent director upon financing close","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amy Mahery appointed as independent Board member effective upon completion of Company's financing.","She will not serve on any Board committees initially.","Compensation will follow standard non-employee director program as previously disclosed.","No other changes to Board or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264556,"accession_number":"0001683168-23-009006","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CNS Pharmaceuticals holds virtual investor update; no specific results disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company held a virtual update meeting on Dec 21, 2023 with CEO John Climcao and CMO Dr. Sandra Silberman.","Meeting link provided in filing but no financial or clinical data included in the 8-K.","Filing under Regulation FD; no material new information furnished in the report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264555,"accession_number":"0001683168-23-008901","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"DSMB recommends CNS Pharma's Berubicin trial continue unmodified after interim analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended continuation of Berubicin vs. Lomustine Phase 2/3 trial in recurrent GBM based on comparable overall survival.","Enrollment expected to complete early Q1 2024; primary endpoint is overall survival.","CEO John Climaco stated recommendation reflects acceptable efficacy and safety as defined in protocol.","FDA has granted Fast Track and Orphan Drug Designation for Berubicin for malignant glioma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264554,"accession_number":"0001683168-23-008159","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CNS Pharma Q3 net loss $4.5M; Berubicin enrollment at 239, interim data Dec 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.5M vs $3.4M in Q3 2022; R&D expenses rose to $3.4M on clinical progress.","Cash at Sept 30 was $0.9M; raised $2.6M in October via warrant/ATM; expects to fund operations through Q4 2023.","Enrollment in potentially pivotal Berubicin GBM study reached 239 patients; full enrollment expected Dec 2023.","Topline data from interim analysis expected in December 2023; 45 of 60 trial sites activated across US and Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264553,"accession_number":"0001683168-23-007238","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CNS Pharmaceuticals posts investor video on Berubicin trial","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO John Climaco discusses Berubicin clinical trial in Virtual Investor event.","Event link posted on October 18, 2023; no financial data or trial results disclosed in 8-K.","No specific quantitative updates or forward guidance provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264552,"accession_number":"0001683168-23-007207","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CNS Pharma raises ~$2.4M via warrant exercise; issues new inducement warrants for 3.76M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercised Existing Warrants for 1,878,000 shares at reduced exercise price of $1.28 per share.","Company issued Inducement Warrants to purchase up to 3,756,000 shares (200% of exercised shares).","New warrants exercisable from six-month anniversary for five years, with a $1.28 strike price.","Gross proceeds of about $2.4M; net proceeds to be used for general corporate purposes.","Financial advisor A.G.P./Alliance Global Partners received $145,000 fee for the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281792,"accession_number":"0001683168-23-006528","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"CNS Pharma shareholders approve director slate, auditor, and 2020 equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 director nominees elected with majority votes; broker non-votes of 1.4M shares.","Ratified MaloneBailey LLP as independent auditor for FY2023 (1.7M for, 40k against).","Approved amendment to 2020 Equity Plan, increasing shares by 745,800 to total 845,800.","Equity plan amendment also modified annual award limits per Participant.","Director election and equity plan amendments each had 1.4M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281791,"accession_number":"0001683168-23-005908","cik":1729427,"company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CNS Pharma receives Nasdaq delisting notice for failure to meet $2.5M equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified CNS Pharma on Aug 17, 2023 of non-compliance with $2.5M stockholders' equity minimum (Rule 5550(b)(1)).","Company also does not meet alternatives of market value of listed securities or net income from continuing operations.","No immediate delisting; company has 45 calendar days to submit a plan. Nasdaq may grant up to 180-day extension if plan accepted.","If plan rejected, company may appeal to Nasdaq Hearings Panel; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7029569.802734374,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-18T23:59:59+00:00|281791"}